To present the recent advances in needle guidance and robotic ultrasound technology which are used for prostate cancer (PCa) diagnosis and management.
INTRODUCTION
Prostate cancer (PCa) is the most common nondermatologic malignancy is US men. Over 1 million transrectal ultrasound (TRUS)-guided biopsies are performed annually in the USA, with an estimated cost burden of over $2 billion [1,2 && ]. Although TRUS-guided prostate biopsy is the most commonly performed procedure to diagnose PCa, it has significant shortcomings. Primarily, biopsy cores are often clustered, instead of the intended biopsy schema, resulting in suboptimal sampling of the whole prostate gland [3-5,6 & ]. Secondly, standard, freehand TRUS biopsy technique does not allow precise localization of a lesion or resampling of an area of interest. As the quality of biopsy core sampling and the biopsy core distribution are associated to cancer detection rate [7] [8] [9] [10] , improved sampling technique should enhance PCa detection and, ultimately, its management.
One strategy to overcome these limitations of the standard TRUS biopsy is to supplement the current TRUS biopsy platform with a steady and reproducible motion device, such as a robot, and three-dimensional (3D) reconstruction software. Similarly, a robotic ultrasound application can provide image stability and guidance during common PCa treatment options such as brachytherapy and radical prostatectomy. This article reviews the contemporary literature on the robotic application for the diagnosis and management of PCa.
]. To overcome the limitations of the standard biopsy technique, two commercial systems are currently available that allow 3D schemata for prostate biopsies.
The TargetScan system (Envisioneering Medical Technologies, Pitsburgh, Pennsylvania, USA) is a system that was originally developed for brachytherapy and has been adapted for office-based, templateguided prostate biopsies. The system comprises a TRUS probe and transducer and software to aid in the 3D mapping of the prostate. The system's conformational software creates a 3D model of the prostate and a resultant biopsy schema. The software saves each biopsy co-ordinate [11] . In a multicenter review, the technology had a 36% cancer detection rate in 140 biopsied patients with 52% accuracy of predicting disease after radical prostatectomy [12] . One detriment of the system, however, is that the 3D image and biopsy template does not change with patient position and prostate deformation. Patient movement may cause errors between the planned template and the executed biopsy. Although the technology can theoretically be used in an awake patient with local anesthesia, the inability to adjust to a moving patient makes general anesthesia the necessity [13] . The system has been primarily designed for prostate brachytherapy. As it uses lateral-fire ultrasound probes, the prostate may only be accessible using a bendable needle that is inserted parallel to the TRUS probe, but exits at 458. This compromises the targeting accuracy and causes frequent aborted procedures because of the needle jamming [14] .
The Artemis system (Eigen Inc., Grass Valley, California, USA) is the other prostate biopsy system using 3D technology. This system provides real-time 3D images and ultrasound probe localization. It comprises a mechanical arm with four degrees of freedom (4 DoF) which controls an end-fire two-dimensional (2D) ultrasound probe. The system creates a 3D picture of the prostate by obtaining sequential axial images and can facilitate MRI/TRUS guided biopsies [15] . Three-dimensional images are stored and can facilitate repeat biopsies. A review of the Artemis system by Natarajan et al. [16] demonstrated that in a digital model, one could rebiopsy within 1.2 mm of a previous biopsy. However, this finding needs to be confirmed in a pure tissue model as patient movement, prostate deformation, and needle deformation may not be accurately reflected in a mathematical model. In addition, the probe movement in the Artemis system is controlled manually, reducing its ability to scan the prostate for imaging. In addition, an operator has to manually set and maintain the trajectory of the needle during biopsy. Although both TargetScan and Artemis systems offer clear advantages compared with freehand TRUS-guided prostate biopsy, they also have distinct limitations as listed above. As a result, these systems have not become widely used in clinical practice.
Several MRI-TRUS fusion (registration) methods are currently investigated [17] [18] [19] [20] [21] . Preacquired MRI is registered to 3D TRUS, typically acquired with special 3D probes. The biopsy procedure is conducted as usual based on the ultrasound, but with the aid of the fused MRI. The main technical limitation is that targeting accuracy is gauged based on the outdated MRI. Temporal differences, patient repositioning from the MRI supine to the TRUS decubitus position, different prostate compressions with the transrectal coil in the MRI, and the TRUS probe [22] , all these contribute to the differences between the shapes of the prostate acquired with MRI and TRUS. These make the accuracy of fusion difficult to quantify, especially after the initial alignment [23] . Consequently, biopsy targeting accuracy relative to the MRI is uncertain, even though it appears to be correct in TRUS and fusion. Several clinical trials are in progress to investigate the efficacy of these methods. Direct MRI-guided prostate targeting methods that typically involve the use of robotic devices are also explored [24] [25] [26] . Compared to preacquired images, direct image guidance (DIGI) eliminates imagefusion errors, provides interventional PCa imaging feedback, and may reduce prostate motion and deformation errors [27] .
ROBOT-ASSISTED PROSTATE BIOPSY
All the aforementioned, 3D TRUS-guided biopsy systems include image guidance, but the TRUS probe is still handled by hand. There are several potential advantages of using a robot to handle the probe: scanning motion can render uniformly distributed 2D image slices for 3D reconstruction; the needle guide can be automatically aligned on
KEY POINTS
Robotic transrectal ultrasound is an emerging technology to improve prostate biopsy schema and needle localization.
TRUS robots have been applied to 12-core trans-rectal biopsy techniques, perineal biopsies, brachytherapy, and laparoscopic and robotic-assisted prostatectomy procedures.
Further advances are required before the technology can be adopted for daily clinical use. target and locked in place for biopsy; and prostate deformations because of the interaction with the probe can be minimized as the same motion can be used for both scanning and aligning the probe for biopsy. In a recent simulation study, Han et al. demonstrated that TRUS probe-holding, robotassisted prostate biopsies had greater accuracy and precision, and improved cancer detection rates compared with freehand, TRUS-guided biopsies by urologists [6 & ,28]. For example, the robot's mean targeting error was 1.0 mm compared to 9.0 mm for the urologists. More importantly, robotic prostate biopsy was associated with a higher significant cancer detection rate of 43% compared with 36% in freehand prostate biopsy by urologists (P < 0.0001).
Although most urologists today perform transrectal prostate biopsies, some argue that transperineal biopsies are preferable as they can be performed sterilely with decreased risk for procedure-related sepsis. However, most of these systems require a perineal brachytherapy template and general anesthesia for a patient. Robotic systems for transperineal biopsies have been developed that incorporate 3D mapping with a needle system, which only requires one or two perineal needle insertion sites [29, 30] . Long et al. [31] reported their robotic transperineal biopsy experience, in which the system could respond to intraprocedural prostate motion. Limitations to this transperineal approach were that anterior zone sampling may be challenging in a patient with an enlarged prostate and the fixed needle insertion may cause needle insertion into the urethra, dorsal vein complex, or neurovascular bundles (NVBs) [32 & ].
ROBOT-ASSISTED BRACHYTHERAPY
Most transperineal prostate biopsy templates were initially developed for brachytherapy, which requires ultrasound imaging and accurate seed implantation in a 3D conformational space. Inaccurate needle placement during brachytherapy can lead to insufficient radiation dosing or radiationinduced side-effects to the rectum, urethra, and bladder. Most current brachytherapy systems require manual placement of the TRUS probe and brachytherapy needles. However, robots can provide stable image acquisition, tracking, orientation, and needle placement, and allow more accurately and precisely placed brachytherapy probes [33, 34] . Robotic brachytherapy platforms may provide additional benefits: robotically guided needles can be placed with increased velocity when compared with manually placed needles, which potentially translates to decreased prostate motion [35] . The technology may further allow for decreased needle deflection and tissue deformation [36] , potentially decreased radiation exposure to operating personnel, decreased procedure times, and therefore the potential for less intraprocedural edema [37, 38] .
Wei et al. [33] developed a robot-assisted brachytherapy system which combined the robot for stabilization and accuracy with a 3D image co-ordination system, allowing for consistent and precise needle insertion. They found that the fiducial registration error (FRE) and target registration error (TRE) were improved with the use of the robot. Fichtinger et al. [37, 38] demonstrated that a robotic-assisted brachytherapy platform with computed tomography (CT) is feasible, but that accuracy greatly depended on tissue displacement and needle deflection.
THREE-DIMENSIONAL IMAGING AND MOTION CONTROL
In order for 3D imaging systems to be useful for active surveillance protocols, brachytherapy, or focal therapy for PCa, accurate calibration and rendering of 2D-3D images, real-time imaging, and minimizing errors for patient motion and prostate deformation are critical. The availability of 3D images is a major advance in prostate imaging. The 3D images are typically created from combining real-time 2D images and real-time tracking systems [32 & ], and special ultrasound calibration methods have been developed [39] . Various tracking systems are currently available, which include real-time 3D TRUS probes, optical sensors, magnetic sensors, and mechanical arms which allow tracking of the 2D images [13] . De Silva et al. [40 & ] recently reported a 2D-to-3D registration technique which helped to compensate for prostate motion. The future development of this imaging technology will be essential for further improving robotic-assisted prostate biopsy accuracy and precision.
ROBOTIC ULTRASOUND USE IN LAPAROSCOPIC AND ROBOTIC PROSTATECTOMY
In addition to improving the accuracy of prostate biopsy and brachytherapy fiducial placement, robotic systems have been applied to laparoscopic technology for better visualization and dissection. During radical prostatectomy, preservation of the NVBs is paramount for postoperative recovery of continence and potency. These bundles can be difficult to visualize intraoperatively. TRUS technology with Doppler ultrasound can improve the localization of these bundles and therefore can potentially improve the dissection and preservation.
TRUS imaging was first used with laparoscopy. Ukimara and Gill [41] initially reported using freehand TRUS imaging to visualize the prostate during laparoscopic radical prostatectomy (LRP) without robotic assistance. Next, van der Poel et al. [42] used freehand TRUS for the bladder neck dissection in daVinci (Intuitive Surgical, Sunnyvale, California, USA) robotic-assisted laparoscopic prostatectomy (RALP) and demonstrated that intraoperative TRUS resulted in fewer basal positive margins during a surgeon's initial experience with RALP.
Other groups developed a robotic instrument to hold and manipulate the TRUS probe during RALP. For example, Han et al. [43] used the TRUS robot [28] , a novel robotic device to hold and manipulate the TRUS probe, in combination with 3D reconstruction software and the da Vinci surgical robot to provide intraoperative guidance to identify and preserve the NVBs. The TRUS robot comprises a robotic orientation remote center of motion (RCM) module, which is attached to an ultrasound probe and an arm that attaches to the operating table. The TRUS robot is controlled remotely by the surgeon and has 4 DoF (Fig. 1) .
It measures position without the need for a separate tracker. After setting up the probe, the authors obtained 2D images of each patient's prostate with corresponding location co-ordinates. The images obtained had minimal prostate displacement and deformation, given that the TRUS probe was rotated around its axis. The authors demonstrated the TRUS robot can safely obtain accurate 3D images of the prostate gland and NVBs with minimal setup time. The setup of the tandem robot approach (T-RALP), a photo showing the TRUS robot before docking the daVinci robot, and a 3D reconstruction of the prostate structures based on the TRUS are shown in Fig. 2 . Subsequently, Long et al. [44] reported their experience in using the robotic TRUS to navigate and visualize the NVB release, bladder neck, and apical dissection. One downside to this approach was that it displaced the rectum anteriorly, making the posterior dissection more challenging in a patient with a large prostate. Hung et al. [45] also found that they could use the TRUS to help identify the NVBs and the borders of prostate lesions. They used the robotic technology to maximally preserve the nerves, given the extent of the prostatic lesion.
CONCLUSION
Robotic prostate biopsy and needle localization is an emerging technology, which has the potential to positively affect the PCa diagnosis and management. Significant advances have been made which allow for more precise and accurate localization of the target. Further advances are required to bring this technology available for daily clinical use.
